Patents by Inventor Michiaki Kubo

Michiaki Kubo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Modulating the aryl hydrocarbon receptor system to treat major depressive disorder
    Patent number: 11122997
    Abstract: Materials and methods for treating major depressive disorder by modulating the aryl hydrocarbon receptor system are provided herein.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: September 21, 2021
    Assignees: Mayo Foundation for Medical Education and Research, Ixcela Inc., Duke University
    Inventors: Balmiki Ray, Liewei Wang, Joanna Biernacka, Mark Frye, Richard M. Weinshilboum, Michiaki Kubo, Taisei Mushiroda, Wayne R. Matson, Rima Kaddurah-Daouk
  • MODULATING THE ARYL HYDROCARBON RECEPTOR SYSTEM TO TREAT MAJOR DEPRESSIVE DISORDER
    Publication number: 20180098722
    Abstract: Materials and methods for treating major depressive disorder by modulating the aryl hydrocarbon receptor system are provided herein.
    Type: Application
    Filed: April 15, 2016
    Publication date: April 12, 2018
    Applicants: Mayo Foundation for Medical Education and Research, Ixcela Inc., Duke University
    Inventors: Balmiki Ray, Liewei Wang, Joanna Biernacka, Mark Frye, Richard M. Weinshilboum, Michiaki Kubo, Taisei Mushiroda, Wayne R. Matson, Rima Kaddurah-Daouk
  • Method for detecting HLA-A*31:01 allele
    Patent number: 9879314
    Abstract: Provided is a method for detection of HLA-A*31:01 allele. One or more single nucleotide polymorphisms which characterize HLA-A*31:01 are analyzed and the presence or absence of HLA-A*31:01 is determined based on the result of the analysis.
    Type: Grant
    Filed: February 28, 2013
    Date of Patent: January 30, 2018
    Assignee: RIKEN
    Inventors: Masayuki Aoki, Michiaki Kubo, Naoya Hosono
  • Risk assessment for cutaneous adverse drug reactions from antiretroviral agent
    Patent number: 9557341
    Abstract: The present invention provides a method of predicting the risk of a patient for developing cutaneous adverse drug reaction to non-nucleoside reverse transcriptase inhibitors such as nevirapine by using HLA-B*3505 allele and/or polymorphisms in the CCHCR1 gene.
    Type: Grant
    Filed: December 11, 2009
    Date of Patent: January 31, 2017
    Assignees: MAHIDOL UNIVERSITY, RIKEN, DEPARTMENT OF MEDICAL SCIENCES, MINISTRY OF PUBLIC, THAILAND CENTER OF EXCELLENCE FOR LIFE SCIENCES (OKMD)
    Inventors: Somnuek Sungkanuparph, Sasisopin Kiertiburanakul, Thanyachai Sura, Wasun Chantratita, Soranun Chantarangsu, Angkana Charoenyingwattana, Surakameth Mahasirimongkol, Michiaki Kubo, Taisei Mushiroda, Yusuke Nakamura
  • METHOD FOR DETECTING HLA-A*31:01 ALLELE
    Publication number: 20150072874
    Abstract: Provided is a method for detection of HLA-A*31:01 allele. One or more single nucleotide polymorphisms which characterize HLA-A*31:01 are analyzed and the presence or absence of HLA-A*31:01 is determined based on the result of the analysis.
    Type: Application
    Filed: February 28, 2013
    Publication date: March 12, 2015
    Inventors: Masayuki Aoki, Michiaki Kubo, Naoya Hosono
  • METHOD FOR DIAGNOSING DRUG ERUPTION RISK INDUCED BY ANTIEPILEPTIC DRUG BASED ON SINGLE NUCLEOTIDE POLYMORPHISM IN 21.33 REGION OF SHORT ARM OF CHROMOSOME 6
    Publication number: 20120238455
    Abstract: The genotype of a single nucleotide polymorphism (SNP) existing in the 21.33 region of the short arm of chromosome 6, such as an SNP at the HLA-A locus, is analyzed, and, based on the results, drug eruption risk induced by an antiepileptic drug is diagnosed.
    Type: Application
    Filed: December 7, 2011
    Publication date: September 20, 2012
    Applicant: RIKEN
    Inventors: Yusuke NAKAMURA, Michiaki KUBO, Taisei MUSHIRODA, Takeshi OZEKI
  • RISK ASSESSMENT FOR CUTANEOUS ADVERSE DRUG REACTIONS FROM ANTIRETROVIRAL AGENT
    Publication number: 20110301043
    Abstract: The present invention provides a method of predicting the risk of a patient for developing cutaneous adverse drug reaction to non-nucleoside reverse transcriptase inhibitors such as nevirapine by using HLA-B*3505 allele and/or polymorphisms in the CCHCR1 gene.
    Type: Application
    Filed: December 11, 2009
    Publication date: December 8, 2011
    Applicants: MAHIDOL UNIVERSITY, RIKEN, DEPARTMENT OF MEDICAL SCIENCES
    Inventors: Somnuek Sungkanuparph, Sasisopin Kiertiburanakul, Thanyachai Sura, Wasun Chantratita, Soranun Chantarangsu, Angkana Charoenyingwattana, Surakameth Mahasirimongkol, Michiaki Kubo, Taisei Mushiroda, Yusuke Nakamura
  • GENE ASSOCIATED WITH ARTERIOSCLEROTIC DISEASE, AND USE THEREOF
    Publication number: 20090324610
    Abstract: Two genes implicated in arteriosclerotic diseases such as cerebral infarction were successfully identified by performing genome-wide correlation studies using SNPs by targeting the entire genome. Polymorphic mutations that can be used to examine the presence or absence of risk factors for arteriosclerotic diseases were successfully found on the genes. Subjects can be efficiently examined for the presence or absence of risk factors for arteriosclerotic diseases using the presence or absence of the polymorphic mutations as indicators. Furthermore, methods of screening for therapeutic agents for arteriosclerotic diseases are enabled by using expression or function of the genes as index.
    Type: Application
    Filed: April 24, 2007
    Publication date: December 31, 2009
    Applicants: KYUSHU UNIVERISTY, NATIONAL UNIVERSITY CORPORATION, THE UNIVERSITY TOKYO, HISAYAMA RESEARCH INSTITUTE FOR LIFESTYLE DISEASES, NTT DATA CORPORATION, HUBIT GENOMIX, INC
    Inventors: Yutaka Kiyohara, Mitsuo Iida, Setsuro Ibayashi, Michiaki Kubo, Jun Hata, Yusuke Nakamura, Teruo Omae, Yasuhiro Tanaka, Go Ichien